Shanghai Sonyt Biotechnology Co., Ltd. is one of the leading manufacturers and suppliers of cas:275371-94-3: taspoglutide in China, also supports custom service. Welcome to wholesale bulk high quality cas:275371-94-3: taspoglutide from our factory. Contact us for more details.
| Product Name | CAS:275371-94-3: Taspoglutide |
| Description | Taspoglutide is a new-generation long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It binds to GLP-1 receptors with high affinity, activates the downstream cAMP signaling pathway, and exerts multiple effects including glucose-dependent insulin secretion, glucagon release inhibition, delayed gastric emptying and appetite reduction, effectively improving glycemic control while reducing body weight. With Aib site-specific mutation and fatty acid side chain modification, it has greatly enhanced peptidase resistance and prolonged in vivo half-life, supporting once-weekly administration. In type 2 diabetes and obese animal models, it dose-dependently reduces blood glucose and body weight gain. It is a core tool peptide for type 2 diabetes mechanism research and long-acting GLP-1 peptide drug development. |
| Peptide Purity (HPLC, %) | 95% / 98% / 99% |
| Free base molecular formula | C₁₅₄H₂₅₀N₄₂O₄₇ |
| Free base molecular weight (Da) | 3433.87, higher for salt form |
| Structure type | Linear modified peptide, Aib mutation + fatty acid side chain modification, free peptide / acetate salt |
Product Basic Information Table
| Product Standard English Name | Product Abbreviation / Alias | Function Tags (comma-separated) | Core Structure | Molecular Formula | Exact Mass (Da) | Average MW (Da) | Salt Form | Length (aa) |
| Taspoglutide | Taspoglutide; long-acting GLP-1 analog | Long-acting GLP-1 receptor agonist, glucose lowering & weight loss, DPP-4 resistant, extended dosing interval | GLP-1 analog; Aib mutation at position 8 resists DPP-4 degradation, fatty acid side chain modification prolongs in vivo half-life, highly selectively activates GLP-1 receptors | Free base: C₁₅₄H₂₅₀N₄₂O₄₇ | 3431.84 | 3433.87 | Free peptide / acetate | 30 |
Physicochemical Solubility & Storage Parameters
| Product Code | Appearance | Long-term Storage | Short-term Storage | Solution Stability | Solid Powder Stability |
| PEP-TAS001 | white powder | Store at -20°C, sealed, dry and protected from light, under nitrogen atmosphere. Aliquot to avoid repeated freeze-thaw cycles. | Stable for 2 years at 2–8°C in sealed dry condition; stable for short-term shipping at ambient temperature, suitable for room temperature logistics. | Stable for 7 days at 4°C. Solubility: ~100 mg/mL in DMSO (sonication required); slightly soluble in pure water. Prepare aqueous solution by serial dilution from DMSO stock. Fatty acid side chain tends to cause peptide aggregation; avoid repeated freeze-thaw. | Stable for 3 years at -20°C and 2 years at 4°C, dry and protected from light. |
Functional Description
| Product Code | Frontend Short Summary (for search list display) | Detailed Biological Function Description | Applicable Research Areas (comma-separated) | Targets / Pathways |
| PEP-TAS001 | Aib-mutated long-acting GLP-1 agonist with potent glucose lowering and weight loss for weekly dosing | Taspoglutide is a new-generation long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It binds to GLP-1 receptors with high affinity, activates the downstream cAMP signaling pathway, and exerts multiple effects including glucose-dependent insulin secretion, glucagon release inhibition, delayed gastric emptying and appetite reduction, effectively improving glycemic control while reducing body weight. With Aib site-specific mutation and fatty acid side chain modification, it has greatly enhanced peptidase resistance and prolonged in vivo half-life, supporting once-weekly administration. In type 2 diabetes and obese animal models, it dose-dependently reduces blood glucose and body weight gain. It is a core tool peptide for type 2 diabetes mechanism research and long-acting GLP-1 peptide drug development. | Type 2 diabetes mechanism study, obesity research, long-acting peptide drug development, GLP-1 receptor function study, glucose & lipid metabolism regulation | Glucagon-like peptide 1 receptor (GLP-1R); Glucose metabolism regulation and gastric emptying inhibition pathway |
Hot Tags: cas:275371-94-3: taspoglutide, China cas:275371-94-3: taspoglutide manufacturers, suppliers, factory, 129954-34-3, Cagrilintide, CAS 2381089 83 2, Melanotan I acetate, Retatrutide, Selank
